What's Happening
A new policy push from the Department of Health and Human Services is putting psychiatric prescribing habits under a microscope. HHS has raised concerns about what it calls "psychiatric overprescribing"—the practice of loading patients with multiple psychiatric medications, sometimes for years, without meaningful reassessment of whether those medications are still working.
But clinicians and researchers are pushing back on the framing. Writing in Psychiatric Times, experts argue that the real issue isn't just how many medications patients are on—it's whether those medications are actually helping. The call is for nuanced deprescribing: a deliberate, clinically supervised process of tapering or stopping treatments that aren't delivering results, while simultaneously identifying evidence-based alternatives that might work better for that specific patient.
In other words, the goal isn't to take medications away from people who need them. It's to stop the inertia of keeping patients on treatments that have failed, simply because stopping feels risky or complicated.
Why This Matters Beyond the Policy Debate
For anyone researching ketamine therapy, this conversation hits close to home. The majority of patients who pursue ketamine treatment arrive after a long journey through conventional psychiatric care—often after trying two, three, or more antidepressants without adequate relief. That's actually the clinical definition of treatment-resistant depression (TRD), and it's one of the most well-established indications for ketamine.
The deprescribing debate implicitly validates something ketamine clinicians have been saying for years: staying on a medication that isn't working isn't a neutral choice. It carries its own risks—side effects, delayed recovery, loss of hope, and the cumulative cost of ineffective treatment. The question isn't whether to change course, but how and toward what.
This is where ketamine enters the picture as more than just a last resort. IV ketamine and esketamine nasal spray (Spravato) are now supported by substantial clinical evidence for treatment-resistant depression. They work through a fundamentally different mechanism than SSRIs or SNRIs—targeting the glutamate system rather than serotonin—which is precisely why they can succeed when traditional antidepressants haven't.
Compare evidence and options
Compare ketamine with other treatment paths using neutral explainers.
Compare optionsThe Role of Evidence-Based Alternatives
The experts quoted in Psychiatric Times emphasize that responsible deprescribing isn't just about stopping medications—it requires a plan for what comes next. That's a meaningful distinction. Tapering off an antidepressant without a clinical support structure can be destabilizing, and patients should never attempt it without guidance from a prescriber who knows their full history.
But when a patient and their provider agree that a current medication regimen isn't working, this policy moment may actually support the case for exploring alternatives like ketamine. Esketamine (Spravato) already carries FDA approval for treatment-resistant depression and is covered by many insurance plans when criteria are met. IV ketamine, while used off-label for depression, has a deep evidence base and is offered through licensed clinics across the country. Both represent genuine, evidence-grounded options—not fringe alternatives—for patients whose first-line treatments have come up short.
Importantly, ketamine is typically administered in a clinical setting with monitoring, which aligns with the supervised, thoughtful approach the deprescribing advocates are calling for. It isn't a self-directed workaround; it's a structured intervention with a trained provider involved at every step.
Key Takeaway for Patients
If you've been on psychiatric medications for months or years without meaningful improvement, the current policy conversation gives you a framework to have a direct conversation with your provider: Is this still the right treatment for me? What are the evidence-based alternatives? Ketamine—whether IV infusions or FDA-approved Spravato—may be worth discussing, particularly if your history meets the threshold for treatment-resistant depression. Never taper or stop medications on your own; always work with a prescriber.
The Bigger Picture for Ketamine Patients
Policy debates about prescribing rarely move fast, and this one will unfold over months or years. But the cultural shift it reflects is already real: both clinicians and regulators are increasingly asking hard questions about whether psychiatric treatment plans are being reassessed with enough frequency and rigor.
For patients, the practical implication is permission to ask those same questions. If your current regimen isn't working, you don't have to wait for a federal policy to change before having that conversation. Evidence-based alternatives exist now, they are accessible through licensed providers, and the clinical case for considering them has never been stronger.
Read the original analysis in Psychiatric Times for a deeper look at the clinical arguments around deprescribing and the expert perspectives shaping this debate.
Share
Related Reading
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.